tests the compounds inhibit the electroshock induced convulsions in the mouse e swinyard j am pharm assoc scient ed 38 201 1949 and j pharmacol exp ther 106 319 1952 in this test mice received the test substance in a dosage of 0 1 100 mg kg iv at a given time 30 sec to 50 min following the drug administration 50 ma 200 ms long shock was applied with corneal electrodes smeared with electrolyte jelly this supra threshold shock produces tonic extensor convulsions of all extremities inhibition of the hindlimb extension is taken as a protective action after investigation of several dose levels and times an ed 50 is estimated compounds of this invention have ed 50 39 s ranging from 0 5 30 mg kg as a result of their nmda receptor antagonism the compounds of this invention are useful in the treatment of anxiety schizophrenia and depression or of cns degenerative disorders such as huntington 39 s disease als alzheimer 39 s or parkinson 39 s diseases the compounds of this invention protect further against hypoxia induced degeneration of rat hippocampal neurons in vitro and thus may be useful in disorders arising from cerebral ischemia such as stroke heart attack or.